Merlotti L, Roehrs T, Koshorek G, Zorick F, Lamphere J, Roth T
Sleep Disorders and Research Center, Henry Ford Hospital, Detroit, Michigan 48202.
J Clin Psychopharmacol. 1989 Feb;9(1):9-14.
This study determined the dose effects of zolpidem in 12 healthy males with normal sleep patterns. Subjects spent 7 weeks, 3 consecutive nights per week, in the laboratory and had a 4-night washout between treatments. The first week was a screening and adaptation week. Then subjects received zolpidem (2.5, 5.0, 7.5, 10.0, or 20.0 mg) or placebo on the first two nights for each of the next 6 consecutive weeks. Treatments were organized in a Latin square design and administered in a double-blind fashion. On the third night of each treatment, subjects always received placebo. The 5.0 mg and larger doses of zolpidem significantly decreased latency to persistent sleep and wake before sleep. Sleep maintenance measures were not affected by zolpidem. The 7.5 mg and higher doses of zolpidem significantly increased total sleep time. The only significant sleep stage effect was a decrease in percent of rapid eye movement sleep at only the 20 mg dose. No consistent discontinuation effects were found. Zolpidem was hypnotically active at doses as low as 5.0 and 7.5 mg, and sleep stage effects occurred only at the 20 mg dose, thus separating the dose range of hypnotic and sleep stage effects.
本研究确定了唑吡坦对12名睡眠模式正常的健康男性的剂量效应。受试者在实验室度过7周,每周连续3个晚上,并在各治疗阶段之间有4个晚上的洗脱期。第一周为筛查和适应周。然后,在接下来连续6周的时间里,受试者在前两晚分别接受唑吡坦(2.5、5.0、7.5、10.0或20.0毫克)或安慰剂治疗。治疗采用拉丁方设计,并以双盲方式给药。在每种治疗的第三晚,受试者始终接受安慰剂。5.0毫克及更大剂量的唑吡坦显著缩短了持续睡眠的潜伏期和睡前觉醒时间。睡眠维持指标不受唑吡坦影响。7.5毫克及更高剂量的唑吡坦显著增加了总睡眠时间。唯一显著的睡眠阶段效应是仅在20毫克剂量时快速眼动睡眠百分比降低。未发现一致的撤药效应。唑吡坦在低至5.0毫克和7.5毫克的剂量时具有催眠活性,且睡眠阶段效应仅在20毫克剂量时出现,从而区分了催眠和睡眠阶段效应的剂量范围。